

PTQ/SB/088 (12-07)

Approved for use through 12/31/2007, OMB 0851-0033 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	e required to respond to a callection of information unless it contains a valid OMIS contain number.  Complete if Known			
Substitute for form 1449/PTO	Application Number	10/535 504		
INFORMATION DISCLOSURE	Filing Date	05/18/2005		
STATEMENT BY APPLICANT	First Named Inventor	Sanders		
	Art Unit	1645		
(Use as many sheets as necessary)	Examiner Name	Swartz, R		
Shapt 1 of 1	Attorney Docket Number	SAND3.0-003PCT/US		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, oly and/or country where published.	T <sup>2</sup>
/RPS/	·	Rohrbach s, et al, Medline, NLM 11713429, Nov 2001 "Minimally invasive application of Botulinum toxin type A in nasal hypersecretion"	
/RPS/		Ural Murat et al , Medline NLM 14710908 Dec 2003 "Effect of botulinum Toxin type A on nasal symptoms in patients with allergic Rhittits: etc"	
		· ·	
		·	

			·····	
Examiner Signature	/Rodney P. Swartz, Ph.D./	Date Considered	10/03/2008	

\*EXAMINER: Initial if reference considered, whether or not clastion is in conformance with MPEP 609. Draw line through chasten if not in conformance and not

considered, Include copy of this form with next communication to applicant.

1 Applicant's unique catebook endependent expension of the property of the proper Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.